Riskpilot← Back to searchSign inGet full accessNeogene Oy
OYDissolvedY-tunnus 0823798-5Väylätie 18-A1Manufacture of other inorganic basic chemicals · NACE 2013Est. 1990— employees
Revenue 2025
EUR 0
EBITDA margin
—
Equity ratio
94.8%
Financial strength
Net profit 2025
EUR 0
+100% vs 2024
| Revenue | EUR 0 | — |
| EBITDA | EUR 0 | — |
| Net profit | EUR 0 | +100% |
| Total assets | EUR 4K | -1% |
| Equity | EUR 4K | -3% |
| Employees | — | — |
Legal name
Neogene Oy
Y-tunnus number
0823798-5
Legal form
Osakeyhtiö
NACE code
2013 · Manufacture of other inorganic basic chemicals
Founded
13. kesäkuuta 1990
Share capital
EUR 2 523
Employees
—
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Hallituksen jäsenet ja toimitusjohtaja kukin yksin
Company purpose
Yhtiön toimialana on harjoittaa liiketoimintaa biotekniikan, lääketeollisuuden ja diagnostiikkateollisuuden alalla sekä näihin liittyvillä kaupan aloilla. Lisäksi yhtiö voi harjoittaa palvelu- ja konsultointitoimintaa sekä arvopaperikauppaa.
Address
Väylätie 18-A1
Phone
+3580407781122
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | −0 | −0 | −0 |
| EBITDA | −0 | −0 | 0 | −0 | 0 |
| Depreciation & amort. | — | — | −0 | −0 | −0 |
| EBIT | −0 | −0 | 0 | −0 | 0 |
| Net financials | — | — | 0 | 0 | 0 |
| Profit before tax | −0 | −0 | −0 | −0 | 0 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −0 | −0 | −0 | −0 | 0 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 4 | 4 | 4 | 4 | 4 |
| Equity | 4 | 4 | 4 | 4 | 4 |
| Long-term debt | — | — | 0 | 0 | 0 |
| Short-term debt | 0 | 0 | 0 | 0 | 0 |
| Total debt | 0 | 0 | 0 | 0 | 0 |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20212025
Equity ratio
94.8%
This company
38.2%
Market median
+148% vs market
20212025
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20212025
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.05×
This company
0.62×
Market median
+92% vs market
20212025
- Annual report 2025Filed via PRH / YTJ · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
TJ | Audit | 2025 |
LA Deputy Member | Deputy Member | 2005 |
SJ Audit | Audit | 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2005 | |
| Chairperson | 2005 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Neogene Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Tapio Johannes Raappana | Audit | 0 companies |
| Leena Aulikki Korteniemi | Deputy Member | 0 companies |
| Siina Jasmin Raiskio | Audit | 0 companies |
| Reijo Kalevi Vihko | Board of Directors | 0 companies |
| Veli-Markku Korteniemi | Chairperson | 0 companies |